

Amryt Pharmaceuticals 2020 Methodological Note - ABPI Disclosure Reporting

Tax/VAT considerations:	Yearly amounts for each reportable HCP/HCO is disclosed without VAT
Currency (including conversion rates):	All reported amounts are in British pounds. If the payment is made in another currency, the amount is converted to British Pounds with the rate on the date of the payment.
Transfer of Value Date:	For payments related to contracts and services reimbursed or paid directly to the HCP/HCO (check or cash equivalent), the payment date is utilized for reporting.
Multi-year contracts:	The Company reports all payments made to the reported HCPs/HCOs during the submission year. If a contract contemplated payments to be made in subsequent calendar years, those payments will be reflected in those subsequent calendar years' filings.
Cross Border Payments:	The Company will disclose based on the principal address of the HCP/HCO regardless of the location where the payment was made.
Consent:	The contracts for the reported HCPs/HCOs include consent language between the Company and the HCP/HCOs. By signing the contract, the HCP/HCO is consenting to the disclosure of transfers of value. The Company does not require consent to be obtained in a stand-alone document.
Additional notes:	<p>Regarding payments to ECE, there were two invoices that were paid to the organization. Because the original payment occurred in 2020, these payments were reported in the original 2020 ABPI submission. Since then, ECE has provided credits to those invoices in 2021. Amryt has provided an amended 2020 report to account for the credit adjustments.</p> <p>Several HCPs were engaged and participated in a panel for Amryt. However, the HCPs participated without payment. As such, no payments were reported against these HCPs.</p>